CEO
Jane Nicholson is our CEO. With a robust background in both the commercial and non-profit sectors, Jane has been instrumental in shaping, driving, and leading WMUK towards achieving its strategic goals. She joined WMUK in March 2021 and has been passionate about improving patient outcomes for those with Waldenstrom’s macroglobulinaemia through the WM Registry & WMUK.
Experience and Leadership
Jane’s experience in the charity sector includes focusing on enhancing patient care, supporting research initiatives, and advocating for better treatment options. Under her leadership, WMUK has launched several key initiatives including research programmes, production of original education materials for healthcare professionals, and the rollout of the WMUK Support Line.
Contributions and Impact
Jane has spearheaded fundraising efforts and fostered collaborations to drive forward WMUK’s mission. Her commitment to the organisation is evident in her efforts to engage with the community and improve the lives of those affected by WM.
Collaborative Initiatives and Services
Jane’s leadership has facilitated partnerships and alliances, such as the strategic collaboration with Dendrite Clinical Systems to enhance research. Her work ensures that WMUK remains a vital resource for patients, providing support, information, and advocating for better treatment and care standards.
